TRPM8 and osteosarcoma: Notably, strong staining for TRPM8 in clinical samples is found relevant with patients’ overall survival, verifying its potential role as a molecular marker and prognostic indicator in osteosarcoma (OS: 40.0 ± 5.8 months vs 21.6 ± 2.6 months, p = 0.008).